Yahoo Web Search

Search results

1. • 

     ComboMATCH Precision Medicine Cancer Trials

     National Cancer Institute· 2 hours ago

     (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) is a group of precision medicine cancer clinical trials, including a...

2. • 

     What's Going On With Bio-Path Stock? - Bio-Path Hldgs (NASDAQ:BPTH)

     Benzinga· 1 day ago

     BPTH shares are trading higher Monday after the company announced the presentation of interim...

3. • 'Smart warheads' of cancer: Experts' excitement for treatment approach grows

     Becker’s Hospital Review· 1 day ago

     Cancer experts are increasingly optimistic about the potential for antibody-drug conjugates to become a standard treatment approach. The therapies involve attaching chemotherapy ...

4. • 

     Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

     Medical Xpress· 4 days ago

     (ASCO) Annual Meeting. The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy...

5. • Celularity Inc. (NASDAQ:CELU) Sees Large Growth in Short Interest

     ETF DAILY NEWS· 11 hours ago

     Celularity Inc. (NASDAQ:CELU – Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 627,100 shares, a growth of ...

6. • 

     Cancer-fighting antibodies inject chemo directly into tumor cells, upping effectiveness

     NBC NEWS· 2 days ago

     The approach isn’t entirely new: The first antibody drug conjugate was approved by the Food and Drug...

7. • 

     Owasso senior’s graduation cut short due to cancer diagnosis: ‘Just complete shock’

     Tulsa World· 4 days ago

     Tate, 18, was diagnosed with acute myeloid leukemia, an aggressive blood cancer, on Tuesday, May 21...

8. • Small Business - Shelby County Reporter | Shelby County Reporter

     The Shelby County Reporter· 13 hours ago

     Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety PR Newswire SUZHOU, China ...

9. • Rgenta Therapeutics Presents Preclinical Data from Lead Program RGT-61159, a Potent Inhibitor of...

     The Pilot News· 4 days ago

     "The data presented at ASCO 2024 demonstrate efficient and specific modulation of the oncogenic transcription factor MYB, a target that historically has been difficult to drug, by ...

10. • Small Business - The Andalusia Star-News | The Andalusia Star-News

      The Andalusia Star-News· 3 days ago

      In honor of National Cancer Survivor Month this June, the St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is launching its "Cancer-Free Isn't Free" ...